1. Home
  2. CTNM vs ALCO Comparison

CTNM vs ALCO Comparison

Compare CTNM & ALCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • ALCO
  • Stock Information
  • Founded
  • CTNM 2009
  • ALCO 1960
  • Country
  • CTNM United States
  • ALCO United States
  • Employees
  • CTNM N/A
  • ALCO N/A
  • Industry
  • CTNM
  • ALCO
  • Sector
  • CTNM
  • ALCO
  • Exchange
  • CTNM Nasdaq
  • ALCO Nasdaq
  • Market Cap
  • CTNM 248.7M
  • ALCO 257.5M
  • IPO Year
  • CTNM 2024
  • ALCO N/A
  • Fundamental
  • Price
  • CTNM $12.36
  • ALCO $33.99
  • Analyst Decision
  • CTNM Strong Buy
  • ALCO
  • Analyst Count
  • CTNM 4
  • ALCO 0
  • Target Price
  • CTNM $22.75
  • ALCO N/A
  • AVG Volume (30 Days)
  • CTNM 278.0K
  • ALCO 25.8K
  • Earning Date
  • CTNM 11-05-2025
  • ALCO 08-12-2025
  • Dividend Yield
  • CTNM N/A
  • ALCO 0.59%
  • EPS Growth
  • CTNM N/A
  • ALCO N/A
  • EPS
  • CTNM N/A
  • ALCO N/A
  • Revenue
  • CTNM N/A
  • ALCO $44,199,000.00
  • Revenue This Year
  • CTNM N/A
  • ALCO $15.05
  • Revenue Next Year
  • CTNM N/A
  • ALCO N/A
  • P/E Ratio
  • CTNM N/A
  • ALCO N/A
  • Revenue Growth
  • CTNM N/A
  • ALCO N/A
  • 52 Week Low
  • CTNM $3.35
  • ALCO $24.23
  • 52 Week High
  • CTNM $20.30
  • ALCO $35.01
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 73.06
  • ALCO 55.53
  • Support Level
  • CTNM $10.30
  • ALCO $33.51
  • Resistance Level
  • CTNM $13.26
  • ALCO $34.28
  • Average True Range (ATR)
  • CTNM 1.04
  • ALCO 0.61
  • MACD
  • CTNM 0.03
  • ALCO -0.05
  • Stochastic Oscillator
  • CTNM 77.13
  • ALCO 42.70

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About ALCO Alico Inc.

Alico Inc is a Florida-based agribusiness and land management company that primarily focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells primarily Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers most of the revenue as the firm's primary operating business unit.

Share on Social Networks: